☆ 4.7 Article

SARS-CoV-2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients

JOURNAL OF MEDICAL VIROLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron-Infected Immunocompromised Patients

Smaranda Gliga et al.

Summary: Immunocompromised patients infected with Omicron variants experience prolonged viral shedding and the emergence of escape mutations after treatment with sotrovimab. Combination therapy with remdesivir significantly reduces the occurrence of escape variants.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

Remdesivir Resistance in Transplant Recipients With Persistent Coronavirus Disease 2019 (COVID-19)

John Hogan et al.

Summary: This article describes the first cases of independently acquired V792I RNA-dependent RNA polymerase mutation in renal transplant recipients after exposure to remdesivir. The findings underscore the need for enhanced efforts to identify concerning mutations and address their clinical implications.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Virology

Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis

Eloy E. Ordaya et al.

Summary: This study found that most SARS-CoV-2 Omicron subvariants in COVID-19 patients who received Tixagevimab-cilgavimab showed reduced susceptibility to the antibody. Some patients also showed high resistance to Bebtelovimab. The results highlight the importance of genomic surveillance and identification of new resistant variants.

JOURNAL OF CLINICAL VIROLOGY (2023)

添加到收藏夹

Article Immunology

Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy

Zachary A. Yetmar et al.

Summary: This study retrospectively reviewed SOT recipients who developed breakthrough COVID-19 after full vaccination. The results showed that breakthrough COVID-19 can still occur in SOT recipients after full vaccination, but they generally have acceptable outcomes. Anti-spike monoclonal antibody therapy for eligible SOT patients may help mitigate disease progression and improve outcomes.

TRANSPLANT INFECTIOUS DISEASE (2022)

添加到收藏夹

Article Immunology

Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience

John Paul Verderese et al.

Summary: In a real-life clinical setting, neutralizing monoclonal antibody (NmAb) treatment significantly reduced hospital utilization among patients with COVID-19 with mild to moderate disease, especially if received within 4 days after symptom onset.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Surgery

Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge

Christopher Radcliffe et al.

Summary: Monoclonal antibodies and oral antiviral agents have shown to be effective in reducing hospitalizations and deaths in solid organ transplant recipients with COVID-19, according to a retrospective study.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

添加到收藏夹

Article Immunology

Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 (COVID-19) Outcomes in Organ Transplant Recipients During the Omicron Wave

Javier T. Solera et al.

Summary: In an organ transplant population, this study found that receiving >= 3 doses of mRNA vaccine and using monoclonal antibody within 7 days of symptom onset can protect against severe outcomes in patients with vaccine breakthrough COVID-19.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Letter Infectious Diseases

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab

Camille Vellas et al.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons

Philip L. Tzou et al.

Summary: The Stanford Coronavirus Resistance Database (CoV-RDB) collects and curates published data on the neutralizing susceptibility of SARS-CoV-2 variants and spike mutations to antibodies. The database provides an interactive interface for displaying neutralization data at different levels of granularity and offers a sequence analysis program to assist users in determining mutation-detection thresholds.

PLOS ONE (2022)

添加到收藏夹

Article Surgery

COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era

Jessica Hedvat et al.

Summary: This study aimed to investigate the treatment outcomes of novel COVID-19 therapeutics in solid organ transplant recipients. The results showed that patients treated with nirmatrelvir/ritonavir or sotrovimab had a lower risk of hospitalization or death within 30 days compared to those who received no specific treatment.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

添加到收藏夹

Letter Immunology

Outcomes of Solid Organ Transplant Recipients Treated With Antispike Monoclonal Antibodies for Coronavirus Disease 2019 Across Variant Epochs: Impact of Comorbidities and Vaccination

Zachary A. Yetmar et al.

TRANSPLANTATION (2022)

添加到收藏夹

Article Medicine, General & Internal

Severity of COVID-19 among solid organ transplant recipients in Canada, 2020-2021: a prospective, multicentre cohort study

Victoria G. Hall et al.

Summary: Severe COVID-19 disproportionately affects immunocompromised organ transplant recipients in Canada. Factors associated with severe outcomes include age, comorbidities, and immunosuppression. Lung transplant recipients have the highest disease severity and mortality rate. Liver transplant and azathioprine treatment are associated with lower oxygen requirement. Vaccination has no substantial influence on oxygen requirement.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2022)

添加到收藏夹

Article Immunology

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch

Raymund R. Razonable et al.

Summary: This study evaluates the clinical outcomes of sotrovimab and bebtelovimab in high-risk COVID-19 patients. The results show low rates of severe disease after treatment with these monoclonal antibodies during the era dominated by Omicron.

OPEN FORUM INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Transplantation

Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients

Zachary A. Yetmar et al.

Summary: Monoclonal antibodies targeting the spike protein are important for the prevention and treatment of mild-to-moderate COVID-19 in solid organ transplant recipients, but their clinical use should be determined by the evolving epidemiology of SARS-CoV-2 variants in the community.

CURRENT OPINION IN ORGAN TRANSPLANTATION (2022)

添加到收藏夹

Review Immunology

COVID-19 in Immunocompromised Hosts: What We Know So Far

Monica Fung et al.

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to significant morbidity and mortality globally. The impact of the disease on immunosuppressed patients, such as cancer patients and transplant recipients, remains unclear. Further research is needed to determine the risk of COVID-19 severity and death in immunocompromised patients.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study

Olivia S. Kates et al.

Summary: The mortality rate among SOT recipients hospitalized for COVID-19 was 20.5%, with age and underlying comorbidities being the major drivers of mortality, rather than measures related to immunosuppression intensity.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: REGEN-COV reduced the risk of Covid-19-related hospitalization or death, resolved symptoms, and reduced the SARS-CoV-2 viral load more rapidly than the placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network

Yousaf B. Hadi et al.

Summary: Solid organ transplant recipients have a higher risk of hospitalization and acute kidney injury in COVID-19, but this increased risk is mainly due to a higher burden of comorbidities.

TRANSPLANTATION (2021)

添加到收藏夹

Article Immunology

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Ravindra Ganesh et al.

Summary: This study compared the outcomes of high-risk patients who received bamlanivimab and casirivimab-imdevimab, showing similarly low rates of all-cause and COVID-19-related hospitalizations. Factors associated with higher likelihood of hospitalization included chronic kidney, respiratory, and cardiovascular diseases, as well as immunocompromised status.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M. Dougan et al.

Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Zachary A. Yetmar et al.

Summary: This study retrospectively reviewed solid organ transplant recipients who received monoclonal antibody treatment for COVID-19, showing favorable outcomes and minimal adverse effects in this patient population. Early administration of monoclonal antibody therapy appears to be more efficacious.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients

Zachary A. Yetmar et al.

Summary: Monoclonal antibody therapy for COVID-19 appears to be safe and effective with favorable outcomes in solid organ transplant recipients, with earlier administration associated with reduced hospitalizations. No episodes of rejection or anaphylaxis were reported.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.